FDA Declines To Approve Eli Lilly's Eczema Drug
Portfolio Pulse from Vandana Singh
The FDA has declined to approve Eli Lilly's lebrikizumab biologic license application for the treatment of moderate-to-severe atopic dermatitis (eczema). The decision was based on findings from a third-party inspection of a contract manufacturing organization. The FDA had no concerns about the clinical data package, safety, or label for lebrikizumab. No other Lilly products are affected. LLY shares are down 0.77% in premarket trading.
October 02, 2023 | 3:46 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eli Lilly's stock price may be negatively impacted in the short term due to the FDA's decision not to approve lebrikizumab. However, no other Lilly products are affected, which may limit the long-term impact.
The FDA's decision not to approve lebrikizumab could negatively impact Eli Lilly's stock price in the short term as it may affect the company's future revenues and growth prospects. However, the fact that no other Lilly products are affected could limit the long-term impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100